ArticleBiological trace element research2026
Elucidating the Protective Potential of Ferulic Acid Against Sodium Arsenite- Induced Thyroid and Adrenal Toxicity: An Integrated In-Silico Molecular Docking and In-Vivo Experimental Approach.
Article in Biological trace element research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Arsenic is a hazardous environmental contaminant that adversely affects human and animal health. The present study aimed to investigate the potential adverse effects of sodium arsenite (SA) as an endocrine disruptor on the thyroid and adrenal glands. This study also investigated the endocrine-protective effect of ferulic acid (FA) in male rats exposed to SA. Forty male Wistar rats were organized into four groups: Control, FA (50 mg/kg), SA (10 mg/kg), and SA + FA. All substances were administered orally for 28 days. Our findings demonstrated that SA's ability to exert harmful effects was observed microscopically as vacuolation of colloid and follicular cells, as well as adrenal gland cell necrosis. As well as pronounced positive immunoreactivity for Cyclooxygenase-2 (COX-2). Furthermore, SA significantly declined triiodothyronine (T3), thyroxine (T4), and thyroid-stimulating hormone (TSH) serum levels. The expression of nuclear factor kappa β (NF-ƙβ), Interleukin-1 beta (IL-1β), and Nibrin (NBN) genes significantly increased. In contrast, nuclear factor erythroid 2-related factor 2 (Nrf-2) and catalase (CAT) antioxidant genes significantly diminished. Additionally, a docking simulation was performed to explain the binding affinity of FA on BCL2-associated X (Bax) and Cytochrome C (CYCS). Molecular docking demonstrated that FA binds strongly to Bax (ΔG = - 6.87 kcal/mol) and cytochrome C (ΔG = - 6.54 kcal/mol), which could imply a role in affecting mitochondrial apoptosis. In contrast, its high affinity for catalase (ΔG = - 6.30 kcal/mol) aligns with its potential antioxidant and cytoprotective mechanisms. Interestingly, FA administration provided partial protection against the toxic effects of sodium arsenite exposure in the examined organs.
Indexed as
Identifiers
42734887What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.